首页> 外文期刊>Transfusion and apheresis science: official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis >Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The hellenic experience
【24h】

Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The hellenic experience

机译:皮肤T细胞淋巴瘤患者体外光采的管理。希腊经验

获取原文
获取原文并翻译 | 示例
           

摘要

Extracorporeal photopheresis (ECP) is an established therapy for cutaneous T-cell lymphoma (CTCL). The objective of this study was to further explore the clinical efficacy of ECP combined with immunomodulatory agents.Eighteen patients with histologically proven CTCL were followed-up after therapy with ECP, mainly combined with interferon-α or bexarotene.A total of 61% of patients responded to therapy (n=11; CR: 5, PR: 6). Median survival was 51. months, progression free survival was 28. months and response duration was 29±23.9. months.ECP combined therapy was highly effective or had a palliative effect in CTCL resistant to previous treatments.
机译:体外光胆疗法(ECP)是一种针对皮肤T细胞淋巴瘤(CTCL)的成熟疗法。本研究的目的是进一步探讨ECP结合免疫调节剂的临床疗效。对18例经组织学证实为CTCL的患者在ECP治疗后进行随访,主要是与α-干扰素或贝沙罗汀联合治疗,占61%对治疗有反应(n = 11; CR:5,PR:6)。中位生存期为51.个月,无进展生存期为28.个月,反应持续时间为29±23.9。 ECP联合疗法在对先前治疗有抗药性的CTCL中非常有效或具有姑息作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号